Samsung Medical Center
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 14
- Registration Number
- NCT03147404
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
The Efficacy and Safety of Udenafil in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy
Phase 4
- Conditions
- Prostate Cancer With Radical Prostatectomy
- Interventions
- Drug: ZYDENA TAB.75mg(Udenafil 75mg)Drug: Placebo Oral Tablet
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 99
- Registration Number
- NCT03142542
Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX
Phase 4
Completed
- Conditions
- Metastatic Non-Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT03134456
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Young Breast Cancer Cohort Study
- Conditions
- Breast Cancer
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 2000
- Registration Number
- NCT03131089
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold
Phase 4
Terminated
- Conditions
- Coronary Artery DiseaseAtherosclerosisStents
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT03119012
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Prospective Cohort for Adult Hemophagocytosis
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 81
- Registration Number
- NCT03117010
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
Recruiting
- Conditions
- Lymphoma, Non-HodgkinLymphoma, Hodgkin
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 600
- Registration Number
- NCT03117036
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Information and Communication Technology Based Centralized Clinical Trial Monitoring System for Insulin Dose Adjustment
Not Applicable
Completed
- Conditions
- Insulin-dependent Diabetes MellitusDiabetes MellitusInsulin Hypoglycemia
- Interventions
- Device: Algorithm-based feedback messagesDevice: Personal Health Record
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 112
- Registration Number
- NCT03112343
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 44
- Registration Number
- NCT03110484
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
Phase 2
Withdrawn
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Registration Number
- NCT03110510
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath